Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bories

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Leukemia|October 4, 2016
NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosisS Struski, S Lagarde, P Bories, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Leukemia|October 4, 2016
NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosisS Struski, S Lagarde, P Bories, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Pageof 10